Last reviewed · How we verify
Prostaglandin E2
Prostaglandin E2 (PGE2) binds to prostaglandin E receptors (EP1-EP4) on cell surfaces to modulate inflammation, smooth muscle contraction, and various physiological processes.
Prostaglandin E2 (PGE2) binds to prostaglandin E receptors (EP1-EP4) on cell surfaces to modulate inflammation, smooth muscle contraction, and various physiological processes. Used for Cervical ripening and labor induction, Gastric ulcer prevention, Patent ductus arteriosus (in neonates).
At a glance
| Generic name | Prostaglandin E2 |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Drug class | Prostaglandin analog |
| Target | Prostaglandin E receptors (EP1, EP2, EP3, EP4) |
| Modality | Small molecule |
| Therapeutic area | Multiple (Obstetrics, Gastroenterology, Rheumatology) |
| Phase | FDA-approved |
Mechanism of action
PGE2 is an endogenous eicosanoid that acts as a signaling molecule through G-protein coupled receptors. It plays roles in inflammation regulation, vasodilation, uterine contractions, gastric protection, and immune modulation depending on which EP receptor subtype is activated in different tissues.
Approved indications
- Cervical ripening and labor induction
- Gastric ulcer prevention
- Patent ductus arteriosus (in neonates)
Common side effects
- Uterine contractions/cramping
- Diarrhea
- Nausea
- Fever
- Flushing
Key clinical trials
- An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis (PHASE2)
- Effect of Nigella Sativa Toothpaste on Salivary Biomarkers in Patients With Gingivitis (NA)
- Dexamethasone as ESPB Adjuvant in Lumbar Laminectomy (PHASE3)
- PGE2 Followed by Oxytocin vs Oxytocin in Term PROM (POXY-PROM) (NA)
- Comparison of Conventional and Cu-NiTi Archwires Regarding Clinical Efficiency and Pain Intensity Using Prostaglandin E2 Biomarker During Alignment and Leveling (NA)
- Evaluation of the Biomechanical Response of Orthodontic Tooth Movement to Clear Aligner vs Fixed Orthodontic Appliance (NA)
- PGE2/IL-22 Pathway in Various Forms of Eczema
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prostaglandin E2 CI brief — competitive landscape report
- Prostaglandin E2 updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI